Phase II Open Label Trial to Assess the Efficacy and the Imapct on QTcF of Continuous Oral BIBW 2992 at a Daily Dose of 50mg in Patients With Relapsed or Refractory Solid Tumours Including Patients With Brain Metastases and Those With Glioblastoma Not Amenable to Other Therapy.

Trial Profile

Phase II Open Label Trial to Assess the Efficacy and the Imapct on QTcF of Continuous Oral BIBW 2992 at a Daily Dose of 50mg in Patients With Relapsed or Refractory Solid Tumours Including Patients With Brain Metastases and Those With Glioblastoma Not Amenable to Other Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Afatinib (Primary)
  • Indications Brain metastases; Glioblastoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Apr 2011 Planned end date changed from 1 Mar 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top